Loading clinical trials...

Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders

Using Telehealth to Expand Treatment Access for Veterans With Opioid Use Disorder (CDA 18-008)

NCT05348317•VA Office of Research and Development

View on ClinicalTrials.gov

Summary

This project will pilot-test and obtain stakeholder input on a telehealth-delivered substance use disorder (SUD) care model (with initial engagement and ongoing MI-CBT treatment) with the goal of increasing treatment utilization and improving outcomes for rural and non-rural Veterans with SUDs.

Eligibility

Age

18 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Veteran patients at the Ann Arbor VA Healthcare System
•Diagnostic and Statistical Manual of Mental Disorders (DSM-5) SUD diagnosis and/or substance use on average of 2 days a week over the past month
•Telephone access
•Able to provide informed consent

Exclusion Criteria

•Receiving SUD psychotherapy
•Inability to speak or understand English
•Substantial mental health instability or conditions that preclude informed consent (e.g., acute psychosis, cognitive deficits) or understanding of assessment or program content
•Prior alcohol withdrawal seizures or delirium tremens

Locations (1)

VA Ann Arbor Healthcare System, Ann Arbor, MI

Ann Arbor, Michigan, United States

Key Dates

Start Date

May 19, 2022

Primary Completion Date

September 30, 2026

Completion Date

September 30, 2026

Last Updated

August 14, 2025

Enrollment

ACTUAL participants

Conditions

Substance UseSubstance Use DisordersSubstance DependenceVeterans

Interventions

VetReach

BEHAVIORAL

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

NCT04197921

Opioid-use DisorderSubstance Use Disorders

View study

RECRUITINGPHASE4

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

NCT07199335

HIVSubstance Use Disorder (SUD)+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Developing a Telehealth Model to Improve Treatment Access for Rural Veterans With Substance Use Disorders

Inclusion Criteria

Exclusion Criteria

Exablate for LIFU Neuromodulation in Patients With Opioid Use Disorder (OUD) and/or Other Substance Use Disorders (SUDs)

Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs

Primary Connections for Youth and Families

Gii'Igoshimong: Sitting With Your First Family

Web-based Alcohol- or Cocaine-specific Inhibition Training in Adolescents and Young Adults With Substance Use Disorder

Native Spirit: Significant Aim 3: Intervention